About Piramal Pharma Limited (PPL)

Piramal Pharma Limited (PPL) is a Mumbai-headquartered pharmaceutical company incorporated in 2020, with equity shares listed on the stock exchanges on October 19, 2022 . The company operates across three businesses: Piramal Pharma Solutions (an integrated Contract Development and Manufacturing Organisation, or CDMO), Piramal Critical Care (Complex Hospital Generics), and Piramal Consumer Healthcare (OTC health and wellness). PPL services innovation-led customers through end-to-end capabilities spanning discovery, development and commercial manufacturing of drug substances and drug products; it also markets differentiated generics for hospital care and a portfolio of consumer brands in India.

The company’s global footprint comprises 17 development and manufacturing facilities across India, North America and the UK/Europe, and a distribution network spanning over 100 countries. Milestones highlighted by the company include operating the world’s first USFDA‑approved commercial ADC CDMO site at Grangemouth, UK, part of its differentiated capabilities in high‑potency APIs, ADCs, peptides and sterile injectables.

Piramal Pharma Limited’s Business Segments

• Segment contribution to FY2025 revenue: CDMO 59%; Complex Hospital Generics 29%; Consumer Healthcare 12%.
• CDMO revenue by service: Discovery 2%; Development 46%; On‑patent Commercial Manufacturing 27%; Other Commercial Manufacturing 25%.
• CHG revenue by segment: Inhalation Anaesthesia 67%; Intrathecal Therapy 10%; Injectable Anaesthesia and Pain Management 15%; Other Specialty and Generic Products 8%.

Piramal Pharma Limited’s Revenue by Geography

• Domestic vs. International: Exports contributed 68.55% of turnover (International); balance was Domestic.

Piramal Pharma Limited Key Management

• Nandini Piramal – Executive Director, Chairperson
• Peter DeYoung – Executive Director, CEO, Global Pharma
• Vivek Valsaraj – Executive Director, Chief Financial Officer
• Tanya Sanish – Company Secretary

Latest Updates on Piramal Pharma Limited

• Complex Hospital Generics: Maintained leadership in the US for Sevoflurane with a 44% value share and in intrathecal Baclofen (Gablofen) with about 75% value share; renewed and extended key US tenders during FY2025.
• CHG portfolio expansion: Two new injectable products were launched in the US and Europe; Neoatricon (pre‑diluted dopamine for paediatric use) received approvals in the UK, Germany, France and Italy via partner BrePco Biopharma, for which PPL holds marketing and distribution rights.
• Manufacturing scale‑up: Sevoflurane production lines were commenced at Digwal, India, to supplement the Bethlehem (US) site; key starting material capacity was significantly increased at Dahej to deepen vertical integration for inhalation anaesthetics.
• CDMO growth drivers: The project pipeline reached 145 molecules across stages, including 31 in Phase III; the company has executed 127+ integrated, multi‑site projects since 2020.
• Differentiated platforms: Continued multi‑year capex to more than double sterile fill‑finish capacities at Lexington (US) and add payload‑linker capabilities at Riverview (US) as part of a US$ 90 Million programme; ADC capacity expansion at Grangemouth was earlier commercialised.
• Quality and compliance: Cleared 36 regulatory inspections (including two USFDA) and 165 customer audits during the year, continuing a quality‑first record.
• Consumer Healthcare: E‑commerce contributed 21% of segment revenue; distribution now reaches about 1,80,000 chemists/cosmetics shops and 13,000 modern trade outlets, with a D2C site (Wellify) live; over the last four years, 200+ new products/SKUs have been launched, with new launches contributing 8% of PCH sales in the last two years.